FDA Approves Atezolizumab as Adjuvant Treatment for Non-Small Cell Lung Cancer
Evidence for efficacy is based on the results from the IMpower010 study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1533 results
EMA Recommends Granting a Marketing Authorisation for Zanubrutinib for the Treatment of Waldenström’s Macroglobulinaemia
It is indicated in patients who have received at least one prior therapy, or in first-line treatment for patients unsuitable for chemo-immunotherapy
Nivolumab Plus Low-Dose Ipilimumab Demonstrates Clinical Benefit in First-Line Treatment for MSI-H/dMMR mCRC
Findings from the CheckMate 142 study in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer
Adjuvant Abemaciclib Combined with Endocrine Therapy Improves IDFS in HR-Positive, HER2−Negative, Node-Positive, High-Risk, Early Breast Cancer
Updated results from the monarchE study point to abemaciclib benefit regardless of Ki-67 status
Zilovertamab Vedotin Is Safe and Demonstrates Activity In Heavily Pretreated Patients With Lymphoid Malignancies
Findings from a phase I study of selective ROR1 targeting
FDA Approves Pembrolizumab Combination for the First-Line Treatment of Cervical Cancer
Evidence for efficacy is based on the results from the KEYNOTE-826 study
EMA Recommends Extension of Indications for Pembrolizumab
New indication concerns the treatment of PD-L1 positive locally recurrent unresectable or metastatic TNBC
TMB Consortium Develops a TMB Calibration Tool
Statistical calibration allows for comparison of tumour mutational burden values across various panel assays
A Third Dose of BNT162b2 is Safe and Improves Humoural Immunity Against SARS-CoV-2 in Patients with Solid Tumours
Third vaccine dose could be immunologically beneficial for patients on active chemotherapy
Merging the Histologic and Molecular Data Into an Integrated Score Significantly Improves Precision in Stratification of Meningiomas
Integrated molecular-morphologic meningiomas classification by the German Consortium on Aggressive Meningiomas
FDA Recognises OncoKB Database of Molecular Tumour Marker Information
A portion of the OncoKB is recognised as a source of valid scientific evidence for Level 2 and Level 3 biomarkers
FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukaemia
Evidence for efficacy is based on the results from the ZUMA-3 study